A comprehensive comparison of additional benefit assessment methods applied by institute for quality and efficiency in health care and European Society for Medical Oncology for time-to-event endpoints after significant phase III trials: a simulation study
Objectives - After a successful Marketing Authorization Application for clinical trials with time-to-event endpoints, the degree of the added benefit from new treatments remains unknown and needs to be assessed. Unfortunately, until now no clear definition for added benefit determination of a treatm...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
28 October 2022
|
| In: |
Value in health
Year: 2022, Volume: 25, Issue: 11, Pages: 1853-1862 |
| ISSN: | 1524-4733 |
| DOI: | 10.1016/j.jval.2022.05.015 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jval.2022.05.015 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1098301522020034 
|
| Author Notes: | Christopher A. Büsch, Johannes Krisam, Meinhard Kieser |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1839123745 | ||
| 003 | DE-627 | ||
| 005 | 20250711133432.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230314s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jval.2022.05.015 |2 doi | |
| 035 | |a (DE-627)1839123745 | ||
| 035 | |a (DE-599)KXP1839123745 | ||
| 035 | |a (OCoLC)1389534385 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Büsch, Christopher |d 1993- |e VerfasserIn |0 (DE-588)1207950254 |0 (DE-627)1694285685 |4 aut | |
| 245 | 1 | 2 | |a A comprehensive comparison of additional benefit assessment methods applied by institute for quality and efficiency in health care and European Society for Medical Oncology for time-to-event endpoints after significant phase III trials |b a simulation study |c Christopher A. Büsch, Johannes Krisam, Meinhard Kieser |
| 246 | 3 | 0 | |a three |
| 264 | 1 | |c 28 October 2022 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar 28. Juni 2022, Artikelversion 28. Oktober 2022 | ||
| 500 | |a Gesehen am 14.03.2023 | ||
| 520 | |a Objectives - After a successful Marketing Authorization Application for clinical trials with time-to-event endpoints, the degree of the added benefit from new treatments remains unknown and needs to be assessed. Unfortunately, until now no clear definition for added benefit determination of a treatment exists. Nevertheless, European authorities / societies have developed 2 “additional benefit assessment” methods, which have up to now not been compared: the European Society for Medical Oncology (ESMO) developed a dual rule considering relative and absolute benefit. The German Institute for Quality and Efficiency in Health Care (IQWiG) developed a method using upper 95% hazard ratio confidence interval. - Methods - We evaluate and compare both methods in an extensive simulation study including different censoring rates, failure time distributions, and treatment effects for sample size calculation. The methods’ performance is assessed via Receiver Operating Characteristic curves, Spearman correlation, and percentage of achieved maximal scores. - Results - The results show that IQWiG’s method has in many situations a lower maximal scoring proportion than ESMO’s rule, that is, up to 28.5% versus 94.7%. Various failure time distributions lead to strongly changed maximal scoring percentages for ESMO. High positive correlation between the methods is present for moderate treatment effects. - Conclusions - IQWiG’s method is usually more conservative than ESMO’s. ESMO’s rule tends to be more susceptible for various failure time distributions. Using the lower confidence interval limit seems to be a better solution resulting in a higher true-positive rate without increasing the false-positive rate. Thus, IQWiG’s method might need to be adapted accordingly to achieve a better overall classification. | ||
| 650 | 4 | |a additional benefit assessment | |
| 650 | 4 | |a clinical phase III trials | |
| 650 | 4 | |a oncology trials | |
| 650 | 4 | |a survival analysis | |
| 700 | 1 | |a Krisam, Johannes |d 1986- |e VerfasserIn |0 (DE-588)1016031343 |0 (DE-627)705475034 |0 (DE-576)351438696 |4 aut | |
| 700 | 1 | |a Kieser, Meinhard |d 1960- |e VerfasserIn |0 (DE-588)103276547X |0 (DE-627)739277766 |0 (DE-576)168963825 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Value in health |d Amsterdam [u.a.] : Elsevier, 1998 |g 25(2022), 11 vom: Okt., Seite 1853-1862 |h Online-Ressource |w (DE-627)32049117X |w (DE-600)2011039-X |w (DE-576)09116978X |x 1524-4733 |7 nnas |a A comprehensive comparison of additional benefit assessment methods applied by institute for quality and efficiency in health care and European Society for Medical Oncology for time-to-event endpoints after significant phase III trials a simulation study |
| 773 | 1 | 8 | |g volume:25 |g year:2022 |g number:11 |g month:10 |g pages:1853-1862 |g extent:10 |a A comprehensive comparison of additional benefit assessment methods applied by institute for quality and efficiency in health care and European Society for Medical Oncology for time-to-event endpoints after significant phase III trials a simulation study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jval.2022.05.015 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1098301522020034 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230314 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 103276547X |a Kieser, Meinhard |m 103276547X:Kieser, Meinhard |d 910000 |d 911800 |e 910000PK103276547X |e 911800PK103276547X |k 0/910000/ |k 1/910000/911800/ |p 3 |y j | ||
| 998 | |g 1016031343 |a Krisam, Johannes |m 1016031343:Krisam, Johannes |d 910000 |d 911800 |e 910000PK1016031343 |e 911800PK1016031343 |k 0/910000/ |k 1/910000/911800/ |p 2 | ||
| 998 | |g 1207950254 |a Büsch, Christopher |m 1207950254:Büsch, Christopher |d 910000 |d 911800 |e 910000PB1207950254 |e 911800PB1207950254 |k 0/910000/ |k 1/910000/911800/ |p 1 |x j | ||
| 999 | |a KXP-PPN1839123745 |e 4289744508 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Online verfügbar 28. Juni 2022, Artikelversion 28. Oktober 2022","Gesehen am 14.03.2023"],"title":[{"title":"A comprehensive comparison of additional benefit assessment methods applied by institute for quality and efficiency in health care and European Society for Medical Oncology for time-to-event endpoints after significant phase III trials","subtitle":"a simulation study","title_sort":"comprehensive comparison of additional benefit assessment methods applied by institute for quality and efficiency in health care and European Society for Medical Oncology for time-to-event endpoints after significant phase III trials"}],"person":[{"display":"Büsch, Christopher","given":"Christopher","family":"Büsch","role":"aut"},{"family":"Krisam","given":"Johannes","display":"Krisam, Johannes","role":"aut"},{"given":"Meinhard","family":"Kieser","display":"Kieser, Meinhard","role":"aut"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"28 October 2022","dateIssuedKey":"2022"}],"physDesc":[{"extent":"10 S."}],"language":["eng"],"id":{"doi":["10.1016/j.jval.2022.05.015"],"eki":["1839123745"]},"recId":"1839123745","name":{"displayForm":["Christopher A. Büsch, Johannes Krisam, Meinhard Kieser"]},"relHost":[{"recId":"32049117X","id":{"eki":["32049117X"],"doi":["10.1111/(ISSN)1524-4733"],"issn":["1524-4733"],"zdb":["2011039-X"]},"part":{"extent":"10","volume":"25","pages":"1853-1862","text":"25(2022), 11 vom: Okt., Seite 1853-1862","year":"2022","issue":"11"},"disp":"A comprehensive comparison of additional benefit assessment methods applied by institute for quality and efficiency in health care and European Society for Medical Oncology for time-to-event endpoints after significant phase III trials a simulation studyValue in health","physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"pubHistory":["1.1998 -"],"title":[{"title":"Value in health","subtitle":"the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR)","title_sort":"Value in health"}],"origin":[{"dateIssuedKey":"1998","dateIssuedDisp":"1998-","publisherPlace":"Amsterdam [u.a.] ; Malden, Mass. ; Oxford [u.a.] ; Oxford [u.a.]","publisher":"Elsevier ; Blackwell Science ; Blackwell ; Wiley-Blackwell"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 01.12.2023","Fortsetzung der Druck-Ausgabe"]}]} | ||
| SRT | |a BUESCHCHRICOMPREHENS2820 | ||